{"title":"Autophagy inhibitors in the treatment of colorectal cancer: a brief review","authors":"M. Ceci, M. Iezzi, M. Trerotola","doi":"10.36253/ijae-13788","DOIUrl":null,"url":null,"abstract":"Colorectal cancer (CRC) is the third most frequent cancer. The first-line adjuvant or neoadjuvant chemotherapy is represented by 5-fluorouracil (5-FU) but its application is limited due to induction of chemoresistance. Recent studies showed that the 5-FU resistance in CRC is closely related to the activation of autophagy. During human carcinogenesis, autophagy has been demonstrated to play opposite roles of inhibitor or promoter of malignant progression depending on initial or advanced stages of growth. Currently, the autophagy inhibitor chloroquine (CQ) and its derivate, hydroxychloroquine (HCQ), are the only Food and Drug Administration (FDA)-approved drugs for clinical use. This review summarizes recent findings on the possible employment of autophagy inhibitors to overcome chemoresistance engaged in the CRC.","PeriodicalId":14636,"journal":{"name":"Italian journal of anatomy and embryology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian journal of anatomy and embryology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36253/ijae-13788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Colorectal cancer (CRC) is the third most frequent cancer. The first-line adjuvant or neoadjuvant chemotherapy is represented by 5-fluorouracil (5-FU) but its application is limited due to induction of chemoresistance. Recent studies showed that the 5-FU resistance in CRC is closely related to the activation of autophagy. During human carcinogenesis, autophagy has been demonstrated to play opposite roles of inhibitor or promoter of malignant progression depending on initial or advanced stages of growth. Currently, the autophagy inhibitor chloroquine (CQ) and its derivate, hydroxychloroquine (HCQ), are the only Food and Drug Administration (FDA)-approved drugs for clinical use. This review summarizes recent findings on the possible employment of autophagy inhibitors to overcome chemoresistance engaged in the CRC.
期刊介绍:
The Italian Journal of Anatomy and Embryology, founded in 1901 by Giulio Chiarugi, Anatomist at Florence University, is a peer-reviewed journal sponsored by the Italian Society of Anatomy and Embryology. The journal publishes original papers, invited review articles, historical article, commentaries, obituitary, and book reviews. Its main focus is to understand anatomy through an analysis of structure, function, development and evolution. Priority will be given to studies of that clearly articulate their relevance to the anatomical community. Focal areas include: experimental studies, contributions based on molecular and cell biology and on the application of modern imaging techniques; comparative functional morphology; developmental biology; functional human anatomy; methodological innovations in anatomical research; significant advances in anatomical education. Studies that are essentially descriptive anatomy are appropriate only if they communicate clearly a broader functional or evolutionary significance. All papers should be submitted in English and must be original works that are unpublished and not under consideration by another journal. An international Editorial Board and reviewers from the anatomical disciplines guarantee a rapid review of your paper within two to three weeks after submission.